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Background. High blood glucose levels play major roles in the
pathogenesis of renal diabetic complications through non-enzy-
matic glycation. For long-lived molecules this leads to formation
of advanced glycation end products (AGE), and the renal extra-
cellular matrix appears to be one of the targets for such processes.
Using immunocytochemistry, we studied the appearance and
deposition of AGE products in renal tissues from normal and
diabetic rats at different ages, to evaluate the effects of aging and
hyperglycemia.
Methods. The streptozotocin-injected rat represented our
model of hyperglycaemic condition. The immunogold techniques
were applied at the light and electron microscope levels using
specific monoclonal and polyclonal antibodies against AGE ad-
ducts. The results were analyzed by morphometry.
Results. In normoglycemic animals, significant increases in
labeling were detected in tubular basement membranes and
mesangial matrix at 12 to 15 months of age. In contrast, in diabetic
animals, significant increases in labeling were found for all
extracellular matrices as soon as after two months of hyperglyce-
mia. Labelings were also detected in cellular compartments,
particularly in nuclei that showed increases in diabetic condition.
The labeling was particularly intense in proximal convoluted
tubules and their endosomal compartment, due to the reabsorp-
tion of urinary AGE products.
Conclusion. The presence of AGE products in the renal extra-
cellular matrix of old normoglycemic animals and their rapid
appearance in hyperglycemia, indicate that AGE products may
participate in the pathogenesis of renal complications. Further-
more, the non-enzymatic glycation is not restricted to extracellular
matrices but also affects cellular proteins.
Renal glomerulosclerosis is known to occur in normal
animals as a general phenomenon associated with aging
[1–3]. This process appears however, to be amplified when
conditions of chronic hyperglycemia prevail [reviewed in
4–6]. Several morphological and functional alterations
have been described, particularly in the renal glomerulus,
indicating that changes in the molecular organization of the
glomerular extracellular matrix are closely related to mod-
ifications of the glomerular filtration properties. Data are
now available demonstrating that chronic high circulating
glucose levels play major roles in the pathogenesis of
diabetic complications [7–10]. These roles appear to be
mediated, at least in part, by non-enzymatic glycation of
proteins and peptides, a phenomenon that for long-lived
proteins leads to series of oxidative reactions and the
formation of advanced glycation end products (AGEs)
[9–12]. Renal extracellular matrix proteins have been
shown to be the target of the non-enzymatic glycation and
several biochemical studies have reported formation of
Amadori products and accumulation of AGE matrix pro-
teins in tissues as a function of age and diabetes [11–20]. In
addition, it has also been demonstrated that glycation and
transformation into AGE products are not limited to tissue
proteins but also affect circulating serum proteins and
peptides, which by interacting with renal tissue components
can participate in the pathogenicity of the diabetic ne-
phropathy [10, 19–23].
In the present study we took advantage of the availability
of specific anti-AGE antibodies and the immunogold tech-
nique at the light and electron microscope levels to evalu-
ate, by morphological approach, the appearance and dep-
osition of endogenous AGE products in rat renal tissues.
The study was performed in normal and diabetic animals at
different stages of their life to evaluate both the effect of
aging and that of hyperglycemic conditions.
METHODS
An experimental chronic hyperglycemic state was in-
duced in 100 g Sprague-Dawley male rats by a single
intraperitoneal injection of streptozotocin (70 mg/kg body
wt, in citrate buffer 10 mmol/liter, pH 4.5). Control animals
only received the citrate buffer. The streptozotocin-in-
jected animals developed an hyperglycemic state within 48
hours and remained as such throughout the entire length of
the experiment, as demonstrated by the frequent glycosuria
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and glycemia measurements made using the Multistix and
Dextrostix reagent strips (Miles, Ames, Ontario, Canada).
The animals were not treated with insulin. On the other
hand, the sodium citrate-injected animals remained normo-
glycemic. The animals were fed ad libitum with standard rat
chow and had free access to water. The animals were killed
at different time points: 2, 6 and 12 to 15 months upon
injection. Each group was composed of at least three
animals (Table 1). Upon killing the animals, small frag-
ments of kidney cortex were immediately fixed by immer-
sion in periodate-lysine-paraformaldehyde 4% solution
[24] for two hours at 4°C. The tissue fragments were then
rinsed in 0.1 mol/liter phosphate buffer, dehydrated in
methanol and embedded in Lowicryl K4M at 220°C as
described previously [25]. Thin sections were cut, mounted
on nickel grids coated with Parlodion and carbon films. In
addition, larger tissue fragments were sampled, fixed in
Bouin’s fluid and embedded in paraffin. Thick and thin
sections were processed for the immunogold cytochemical
labeling.
Antibodies
Anti-AGE antibodies were obtained by immunization of
rabbits with AGE-BSA as described previously [26–28].
Upon bleeding of the animals, anti-BSA antibodies were
eliminated from the serum by adsorption with BSA and the
anti-AGE IgG fraction was prepared by ammonium sul-
phate precipitation and DEAE chromatography [26]. The
specificity of this antibody was substantiated by immu-
nodot-blotting and double immuno-diffusion on agarose
gels [26]. The antibody was previously applied for the
immunochemical and cytochemical detection in renal tissue
of AGE-BSA and AGE-peptides that were injected into
normal rats [26]. A second specific anti-AGE antibody, the
mouse monoclonal antibody (Clone 6D12; Panapharm
Lab. Co., Kumamoto, Japan), reacting against several AGE
proteins and peptides and recognizing, among others, the
Ne-(carboxymethyl) lysine (CML) adduct [29], was also
used in the present study. Techniques for raising this
antibody, its characterization and application for the im-
munohistochemical detection of AGE products in human
aortic tissues were reported previously [30, 31].
Cytochemical studies
For light microscopy, the tissue sections were deparaf-
finized and rehydrated through decreasing concentrations
of ethanol and, upon five minutes in 10 mmol/liter phos-
phate buffered saline pH 7.4 (PBS), were incubated with
the anti-AGE antibody diluted 1/50 for two hours at room
temperature. Upon rinsing in PBS, the tissue sections were
incubated with the protein A-gold complex for 60 minutes
at room temperature and the reaction was silver-enhanced
according to protocols described in detail previously [25].
For electron microscopy, the grids carrying the tissue
sections were incubated for 60 minutes on a drop of 10
g/liter glycine in PBS. The grids were transferred to a drop
of 10 g/liter ovalbumin and incubated 30 minutes at room
temperature. Next, the grids were incubated overnight at
4°C on a drop of one of the anti-AGE antibodies. The grids
were washed and incubated with protein A-gold or IgG-
gold complexes (15 or 10 nm), depending on the primary
antibody used, for 30 minutes at room temperature [25].
Upon washing with PBS and rising in water, the tissue
sections were stained with uranyl acetate and examined
with a Philips 410 electron microscope. The antibodies
were used at different dilutions, the polyclonal anti-AGE
antibody was diluted at 1:50 while the monoclonal one was
used at 1:10.
The specificity of the immunolabelings was assessed by
several control experiments as described previously [26]. In
particular, labelings were carried out upon adsorption of
the anti-AGE antibody with its specific antigen (AGE-
BSA), upon immunoprecipitation with protein A and upon
omitting the antibody step in the protocol.
Quantitative evaluations
The intensities of the immunolabelings obtained with the
polyclonal antibody were evaluated over different base-
ment membranes and cellular compartments, as described
previously [25]. For each animal, 12 micrographs of each
Table 1. Densitya of labeling for AGE products on different rat renal basement membranes in normal and diabetic conditions
Blood
glucose
mmol/liter
Tubular
BM
Glomerular
BM
Mesangial
matrix
Normal rats
2 months (N 5 3) 5.6 6 0.2 3.26 6 0.90 6.27 6 0.62 4.54 6 0.94
15 months (N 5 5) 7.0 6 0.7 6.36 6 0.34b 6.50 6 0.34 7.11 6 0.71b
Diabetic rats
2 months (N 5 3) 26.6 6 2.9b 8.65 6 0.55b 11.22 6 1.07b 8.01 6 0.71b
6 months (N 5 4) 31.7 6 0.7b 8.97 6 0.66b 8.43 6 0.63b 7.92 6 0.69b
15 months (N 5 5) 24.6 6 2.7bc 7.78 6 0.55b 8.58 6 0.39b 8.05 6 0.56b
a Number of gold particles/mm2
b Values significantly different (at least P , 0.01) from the corresponding value of 2-month-old normal animals
c Values significantly different (P , 0.001) from the corresponding value of age-matched normal animals
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region were recorded and enlarged to a final magnification
of 348,000. The intensity of labeling, as expressed in gold
particles per unit area of the compartment, was determined
using a Zeiss-Videoplan unit (Carl Zeiss Inc., Toronto,
Canada). Among the different renal basement membranes,
those of the glomerular loops, the mesangial matrix and the
tubular ones were analyzed. Based on results obtained by
light microscopy, the labeling present within some cellular
compartments of the proximal tubules epithelial cells was
evaluated. In particular the nuclei, the mitochondria and
the cell cytosol. The comparative evaluations were carried
out between values obtained in normal and hyperglycemic
conditions at each time point, as well as between values
obtained in hyperglycemic conditions and their correspond-
ing ones obtained with the two-month-old normoglycemic
rats, in order to emphasize changes occurring with age as
well as with diabetes. The statistical analysis were per-
formed using the Student’s t-test.
RESULTS
The streptozotocin injection induced an hyperglycemic
state as soon as 48 hours after its administration. High
blood glucose levels were consistently detected in the
animals throughout the entire length of the experiment
that, for some animals, lasted up to 15 months. Blood
glucose levels of the samples recovered at time of death,
listed in Table 1, demonstrate the significance of the
hyperglycemic state. In addition to hyperglycemia, the
long-term diabetic animals developed characteristic cata-
ract lesions and impairment of weight gain [32]. Typical
alterations of diabetic glomerulosclerosis were present in
the renal tissue of the hyperglycemic animals, particularly
in the oldest ones. Thickening of the basement membranes
and accumulation of mesangial matrix were observed,
confirming previous reports [32]. In control normoglycemic
animals, a thickening of the basement membrane was also
registered along with age, but was not as significant as was
found in the hyperglycemic animals.
Application of the anti-AGE antibodies in combination
with the immunogold techniques on renal tissue sections
resulted in a staining of the extracellular matrix. The
labeling was intense in tissues of the 15-month-old hyper-
glycemic animals (Fig. 1). In addition to basement mem-
branes and mesangial matrix, tubular epithelial cells were
also stained. This was particularly evident for the proximal
convoluted tubules that showed an intense cellular staining
(Fig. 1). By electron microcopy, a labeling by gold particles
was found over the different renal basement membranes as
well as in epithelial cells. The labeling by gold particles was
present over the glomerular basement membrane and the
Fig. 1. Light microscopy immunocytochemistry. Renal tissue from a 14-month-old hyperglycemic rat. Application of the anti-AGE antibody in
conjunction with the protein A-gold silver-enhancement protocol results in the staining of the extracellular matrix, quite striking at the level of the
mesangium (arrows). Some renal tubules, particularly the convoluted ones, appear also to be stained (magnification 3500).
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mesangial matrix (Figs. 2 and 3). The peritubular basement
membranes were also labeled (Fig. 4). The labeling was
rather low in normoglycemic animals; it increased with age
and was more significant in tissues from hyperglycemic
animals. The gold particles did not display any particular
distribution, being rather random within the basement
membrane material. In the oldest hyperglycemic animals,
the labeling was occasionally concentrated over small elec-
tron-dense deposits present within the basement mem-
branes and the mesangial matrix (Figs. 3 and 4). Within the
cells, the labeling by gold particles was found to be low but
consistent in various cellular compartments. Increases in
intensity of labeling were registered along with age and in
hyperglycemic condition, particularly over the nucleus
which systematically displayed the highest cellular labeling
(Figs. 2 and 3). In addition, and particularly striking for the
epithelial cells of the proximal convoluted tubules, a label-
ing by gold particles was also present at the level of the
microvilli and the endosomal compartment in the apical
region of the cells (Fig. 5). The lysosomes, aside from a few
that were intensely labeled, showed a lower labeling than
that of the endosomal compartment (Fig. 5). In contrast,
the apical region of the distal tubules epithelial cells
displayed little labeling (Fig. 5). These results confirm the
heterogeneity in staining observed by light microscopy (Fig.
1). Both the polyclonal and the monoclonal antibodies
yielded similar qualitative results, although the monoclonal
one had a tendency to yield higher densities of labeling
(Fig. 4).
These subjective observations were confirmed by the
quantitative evaluations. Tables 1 and 2 report the densities
of labeling over the different regions studied in tissues of
Fig. 2. Electron microscopy immunocytochemistry. (A) Renal tissue of a two-month-old normoglycemic animal. The glomerular wall appears normal
with a thin glomerular basement membrane (GBM). The immunolabeling by gold particles, present over the GBM, is low. (B) Renal tissue of a
13-month-old hyperglycemic animal. The glomerular wall shows significant morphological changes with a thick glomerular basement membrane (GBM).
The labeling by gold particles is significant, particularly at the level of the GBM and the nuclear matrix (N). Some gold particles are also seen over the
endothelial cell cytoplasm. Abbreviations are: US, urinary space; Cap, blood capillary (magnification, A 335000; B, 325000).
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normal and hyperglycemic animals as obtained with the
polyclonal antibody. A small increase in AGE labeling
was detected in the extracellular matrix along with age,
the most significant occurring at the level of the mesan-
gium and the tubular basement membrane. Of particular
interest was the little change found for the glomerular
basement membrane. In hyperglycemic conditions, the
increase in density of labeling was detected as soon as
upon two months of hyperglycemia, but no further
increase took place in conjunction with the age of the
animals. In this case, the significant increases in AGE
labeling were registered in all the basement membranes.
In what concerns the intracellular labeling, the quanti-
tative evaluation (Table 2) confirmed the intense label-
ing present over the nuclei. The labeling did increase
significantly with the age of the animal and with the
hyperglycemic state. Only small changes were detected
over the mitochondria and the cytosol.
Control experiments, performed to assess the specificity of
the different labelings, led to major decreases in labeling
intensities. Indeed, adsorption of the anti-AGE antibody with
BSA-AGE, but not BSA, as well as immunoprecipitation of
the antibodies with protein A resulted in a striking reduction
of the labelings, few gold particles being scattered throughout
Fig. 3. Renal tissue from a 15-month-old
hyperglycemic animal. The mesangial matrix
(MM) appears expanded and significantly
labeled by gold particles. In some instances, the
labeling is concentrated over small dense
deposits (arrows). The nuclei (N) also display a
labeling by the gold particles (magnification
318000).
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Fig. 4. Renal tissue from a 15-month-old hyperglycemic animal. Application of the polyclonal (a) and monoclonal (b) antibodies. The tubular basement
membranes (TBM) appear thick and labeled by gold particles. Basement membrane dense deposits are occasionally labeled (arrow). A labeling is also
present over the epithelial cell cytoplasm (Epi). (c) The result obtained under the control condition in which the monoclonal antibody was adsorbed
by protein A prior performing the labeling protocol. In contrast to panel b, few gold particles are found over the tubular basement membrane (TBM)
or the epithelial cell (Epi) (magnification, a and b, 325000; c, 320000).
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the different structures (Fig. 4). These control experiments
confirm those reported previously [26].
DISCUSSION
By applying specific antibodies to AGE adducts in com-
bination with immunocytochemical techniques, it was pos-
sible, in the present study, to reveal endogenous AGE
products within the renal tissues of normo- and hypergly-
cemic animals. The increase in immunolabeling for AGE
adducts at the level of the renal extracellular matrix was
important upon 15 months of age for the normoglycemic
animals, while it was already significant in tissues of the
young diabetic animals as early as two months of hypergly-
cemia. No further increase in AGE products was detected
along with time in the diabetic animals, suggesting that the
deposition and/or formation of the AGE products in the
renal extracellular matrix occur quite early during diabetes
and thereafter remain in a sort of steady-state condition.
These results are in alignment with those obtained by
biochemical means, demonstrating that circulating as well
as urine AGE-peptides and renal AGE-type IV collagen
increase with age up to 20 months but remain stable
thereafter [16]. This could be due to proteins, which in spite
of being of slow to turn over, still would allow for their
replacement. It could also result from cellular clearance
since AGE-modified molecules are likely to be degraded by
tissue macrophages through their AGE-receptor system
[33] or reabsorbed by the renal tubules as reported previ-
ously [26] and demonstrated in the present study. With the
approach and the reagents used, however, it is not possible
to accurately identify the nature of the revealed AGE
products. One of the antibodies recognizes the CML
adduct [29], but it is clear that several other Maillard
reaction adducts present in the tissues were revealed by
both antibodies. These reaction products could correspond
to deposition of circulating AGE proteins and peptides as
demonstrated previously [26], as well as to glycation of
some of the matrix proteins known to have very slow
turnover cycles. The early glycation detected in circulating
and/or matrix proteins must participate in the onset of the
functional alterations occurring to the glomerular filtration
in diabetic conditions. Indeed, on the one hand absorption
of AGE-adducts triggers several cellular responses includ-
ing cytokine secretion and oxidation enhancing reaction [7],
which could participate in the overall diabetic glomerulo-
sclerosis. On the other hand, the presence of glycated
proteins in circulation is sufficient per se, even in otherwise
normal animals, to induce functional alterations at the level
of the glomerular filtration [34]. In recent studies we have
demonstrated that in contrast to circulating native albumin,
glycated albumin injected to normal animals is rapidly
filtered by the glomerular wall and traverses the glomerular
basement membrane quite easily [34]. When glycated and
native albumin molecules are co-injected into the normal
animal, both forms of the molecule are easily filtered by the
glomerular wall, demonstrating that the sole presence of
circulating glycated proteins induces an alteration in the
permselectivity of the glomerular wall [35]. Similarly, we
have also demonstrated that AGE-peptides injected to
normal animals are rapidly filtered by the glomerular wall,
while AGE-albumin is mainly retained and deposited
within the glomerular basement membrane, thus participat-
ing in the alteration of this matrix [26]. Along this same
line, it has been demonstrated that chronic administration
of AGE-BSA to normoglycemic animals leads to glomeru-
lopathies [8]. Upon reaching the urinary space, both the
glycated and the small AGE-peptides are recovered by the
Fig. 5. Renal tissue from a 15-month-old diabetic animal. The labeling appears quite intense at the level of the apical region of the epithelial cells of
the proximal convoluted tubules (a). The gold particles are particularly associated with the microvilli (mv) and the tubular and vesicular structures of
the endosomal compartment (arrows). In contrast, little labeling is seen on the apical region of the epithelial cells of the distal tubules (b) (magnification
315000).
Table 2. Densitya of labeling for AGE products on rat renal tubular
epithelial cells in normal and diabetic conditions
Nucleus Mitochondria Cytosol
Normal rats
2 months (N 5 3) 16.09 6 1.05 7.43 6 0.52 8.74 6 0.58
15 months (N 5 5) 25.64 6 1.40b 8.22 6 0.38 10.62 6 0.61b
Diabetics rats
2 months (N 5 3) 18.43 6 0.78b 6.48 6 0.31 8.09 6 0.57
6 months (N 5 4) 16.18 6 0.82 7.42 6 0.48 9.86 6 0.51
15 months (N 5 5) 20.42 6 1.54b 10.29 6 0.49b 10.58 6 0.59b
a Number of gold particles/mm2
b Values significantly different (at least P , 0.01) from the correspond-
ing value of 2-month-old normal animal
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tubular epithelial cells through their endosomal compart-
ments [26]. These data indicate that glycated or AGE
serum proteins are handled by the renal tissue as soon as
they are generated, and thus contribute to modifications of
the glomerular wall very early. Besides circulating proteins,
it is also expected that collagen as well as other matrix
proteins known to have very slow turnover are glycated,
become Amadori products, and eventually are transformed
into AGE in conditions of high levels of glucose. This was
previously demonstrated by biochemical means [7, 9, 36–
38]. The crosslinking of the collagen chains resulting from
glycation has been shown to induce an expansion of the
molecular packing of this molecule [39]. In addition, glyca-
tion of basement membrane proteins, induced by chronic
hyperglycemia, has also been linked to modifications in the
net charge of the glomerular wall [37, 40]. All these changes
would in turn render the glomerular wall more permeable,
explaining the fact that, in spite of its thickening, the
basement membranes become more leaky in diabetic con-
ditions [32, 41]. Overexpression of extracellular matrix
proteins [4, 42], cross-linking resulting from non-enzymatic
glycation [39], and secretion of low levels of metallopro-
teinases [43–46] must rapidly promote and lead to accu-
mulation of an altered extracellular matrix in basement
membranes and mesangial regions. We have demonstrated
that major alterations do occur in the molecular structure
of the type IV collagen in the glomerular basement mem-
brane during diabetes [47–49]. Besides shifting towards the
endothelial side of the glomerular wall, this matrix protein
reorganizes itself and adopts a different molecular config-
uration identified as basotubules [49]. The acquisition of
this new molecular conformation was found to take place
upon loss of the permselectivity of the glomerular wall and
could very well result from the glycation and aging of the
molecule. Thus, AGE adducts either from circulation or
from intrinsic origins could participate in the advanced
stages of diabetic glomerulosclerosis.
In otherwise normoglycemic conditions, increases in
AGE-adducts take place along with the aging of the animal
[11, 16, 50–53]. Glomerulosclerosis is known to develop in
normoglycemic subjects as they advance in age [1, 3, 54].
Significant levels of albuminuria and glycosuria have been
reported to occur in old rats, indicating a deterioration of
the glomerular filtration properties [55–57], and again this
alteration is concomitant with the thickening of the glomer-
ular basement membrane. Furthermore, these changes are
correlated to an age-dependant accumulation of AGE
products [14, 18, 58], a correlation supported by the present
results. The increase of AGE labelings in basement mem-
branes was found mainly for the tubular and mesangial
matrices, with little changes for the glomerular one. This is
in agreement with previous biochemical reports showing
smaller changes for the glomerular basement membrane, as
compared to other renal matrices [16]. Thus, the different
aspects of the nephropathy initiated by non-enzymatic
glycation and by the further transformation into AGE
products take place along with age and are enhanced in
diabetic conditions.
The labeling obtained with the anti-AGE antibodies in
certain cellular compartments indicates that non-enzymatic
glycation and transformation into AGE are not limited to
extracellular proteins, but also occur within the cell. Such a
demonstration is in alignment with previous results show-
ing that in vitro cellular and nuclear proteins, as well as
most probably other components such as nucleotides, par-
ticularly those having a very slow turnover, when exposed to
high levels of glucose are glycated and become AGE [59].
Our results showing that AGE immunolabeling detected in
the nucleus increases with age as well as with diabetes is in
keeping with previous work showing that in vitro formation
of AGE-histones is time and sugar concentration depen-
dent [59]. Furthermore, histones isolated from liver tissue
of diabetic rats have been found to have AGE levels
threefold higher than those of their age-matched normo-
glycemic controls [60]. Nuclear AGE-histones isolated
from liver tissue were found to increase with the age of the
animal as well as with the duration of the diabetic state [60].
These data also support the detection of nuclear AGE
immunoreactivity in neural cells [61] and the AGE-BSA-
gold labeling obtained on nuclear matrix [62] that increase
in intensity on tissues from diabetic animals. Previous [60,
63] and present results thus reinforce the concept that
advanced glycation is not restricted to extracellular matrix
and serum proteins but also occurs within cells, particularly
in conditions in which membrane glucose transporters are
not down-regulated. We should thus expect that, similarly
to that which occurs in the extracellular matrix, transfor-
mation of cellular proteins into AGE proteins should
induce modifications of their functional properties.
Concerning the heterogeneity in AGE staining observed
among renal tubular structures by light microscopy and the
intense signal displayed by the proximal tubular epithelial
cells, the electron microscope sheds some light. Indeed,
examination of the proximal tubule epithelial cells showed
intense labeling, particularly at the level of the microvilli
and endosomal compartment (Fig. 5). As demonstrated in
a previous study [26], AGE-peptides and proteins escaping
from the glomerular filtration are present in the urinary
space, and are rapidly and efficiently reabsorbed by the
proximal tubule epithelial cells through their endosomal
compartment and degraded. This is supported by the
demonstration of specific binding of glycated albumin to
isolated renal brush-border membranes vesicles, a binding
that increases with age [64]. Our present observation of
AGE adducts at the level of the endosomal compartment
of the proximal tubule epithelial cells seems to reflect an
important reabsorption.
Transformation into AGE thus appears to be a general
phenomenon that affects extracellular as well as intracel-
lular peptides and proteins. It normally takes place along
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with aging, is enhanced in conditions of hyperglycemia, and
by changing protein conformation could participate to
functional alterations.
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